- Motley Fool•22 hours ago
Here's why Pfizer, Teligent, and Neurocrine Biosciences are all top pharmaceutical stocks to own this year.
Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected
Neurocrine Biosciences has priced its drug Ingrezza, the first approved for adults with the neurological disorder tardive dyskinesia, above even Wall Street’s presumably elevated expectations—at about ...
- PR Newswire•4 days ago
The notes will be sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Neurocrine also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $67.5 million aggregate principal amount of notes. The notes will be senior unsecured obligations of Neurocrine and will accrue interest payable in cash semi-annually in arrears at a rate of 2.25% per annum.
NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||42.00 x 100|
|Ask||62.70 x 300|
|Day's Range||52.56 - 53.85|
|52 Week Range||37.35 - 55.15|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-32.76|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|